PLGA from PolySciTech used in ocular antibiotic delivery system to prevent blindness due to ocular infections.

 

Bacterial Keratitis (BK) is the leading cause of ocular infections leading to blindness. Although antibiotic eyedrops can be used for treatment these tend to have poor drug delivery due to loss through tears and other factors. Using a formulation which adheres to the mucosal layer of the eye can drastically improve drug delivery. Researchers at Birla Institute of Technology & Science-Pilani and LV Prasad Eye Institute use PLGA (cat# AP040) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create PLGA-chitosan conjugate particles. They used these to deliver antibiotic, moxifloxacin, in a nanoparticle formulation to provide improved drug uptake. This research holds promise to prevent blindness by treating ocular infections. Read more: Ch, Sanjay, Sri Ganga Padaga, Balaram Ghosh, Sanhita Roy, and Swati Biswas. "Chitosan-poly (lactide-co-glycolide)/poloxamer mixed micelles as a mucoadhesive thermo-responsive moxifloxacin eye drop to improve treatment efficacy in bacterial keratitis." Carbohydrate Polymers (2023): 120822. https://www.sciencedirect.com/science/article/pii/S0144861723002874

“Abstract: A mucoadhesive self-assembling polymeric system was developed to carry moxifloxacin (M) for treating bacterial keratitis (BK). Chitosan-PLGA (C) conjugate was synthesized, and poloxamers (F68/127) were mixed in different proportions (1: 5/10) to prepare moxifloxacin (M)-encapsulated mixed micelles (M@CF68/127(5/10)Ms), including M@CF68(5)Ms, M@CF68(10)Ms, M@CF127(5)Ms, and M@CF127(10)Ms. The corneal penetration and mucoadhesiveness were determined biochemically, in vitro using human corneal epithelial (HCE) cells in monolayers and spheroids, ex vivo using goat cornea, and in vivo via live-animal imaging. The antibacterial efficacy was studied on planktonic biofilms of P. aeruginosa and S. aureus (in vitro) and Bk-induced mice (in vivo). Both M@CF68(10)Ms and M@CF127(10)Ms demonstrated high cellular uptake, corneal retention, muco-adhesiveness, and antibacterial effect, with M@CF127(10)Ms exhibiting superior therapeutic effects in P. aeruginosa and S. aureus-infected BK mouse model by reducing the corneal bacterial load and preventing corneal damage. Therefore, the newly developed nanomedicine is promising for clinical translation in treating BK. Keywords: Chitosan Poloxamer Mixed micelles Bacterial keratitis Antibacterial Moxifloxacin”

Video: https://youtu.be/RngOUpdlpgE